Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Hyperuricemia model
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Hyperuricemia model" in MCE Product Catalog:
26
26
4
Target:
4
Target:
Research Areas:
Ethambutol is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol can be used to establish animal models of hyperuricemia and optic neuropathy.
1
1 Cited Publications
Cat. No.: HY-B2130S1
CAS No.: 62948-75-8
Uric acid- 15N2 is the 15N-labeled Uric acid (HY-B2130). Uric acid is an orally active oxygen free radical scavenger that helps maintain stable blood pressure and combat oxidative stress. Uric acid can scavenge ROS, such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation. Uric acid can be used as a modeling agent in research on hyperuricemia-induced hypertension models .
Cat. No.: HY-B2130S
CAS No.: 2421217-23-2
Uric acid- 13C, 15N3 is the 15N, 13C-labeled Uric acid (HY-B2130). Uric acid is an orally active oxygen free radical scavenger that helps maintain stable blood pressure and combat oxidative stress. Uric acid can scavenge ROS, such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation. Uric acid can be used as a modeling agent in research on hyperuricemia-induced hypertension models .
Cat. No.: HY-178342
Research Areas:
Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research .
Cat. No.: HY-179030
CAS No.: 3055301-22-6
Target:
Research Areas:
Xanthine oxidase-IN-19 (Compound 13i) is an orally effective inhibitor of xanthine oxidase (XO), with an IC50 of 0.2 μM. Xanthine oxidase-IN-19 can significantly reduce serum uric acid levels in acute hyperuricemia rat models. Xanthine oxidase-IN-19 can be used for the study of acute hyperuricemia .
Target:
Research Areas:
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research .
Cat. No.: HY-162829
Research Areas:
hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics .
Target:
Research Areas:
Ethambutol (Standard) (Emb (Standard)) is the analytical standard of Ethambutol (HY-B0535). This product is intended for research and analytical applications. Ethambutol is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol can be used to establish animal models of hyperuricemia and optic neuropathy.
Cat. No.: HY-W780166
CAS No.: 139290-36-1
Uric acid- 13C is the 13C-labeled Uric acid (HY-B2130). Uric acid is an orally active oxygen free radical scavenger that helps maintain stable blood pressure and combat oxidative stress. Uric acid can scavenge ROS, such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation. Uric acid can be used as a modeling agent in research on hyperuricemia-induced hypertension models .
Cat. No.: HY-B2130AR
CAS No.: 1198-77-2
Synonyms: Monosodium urate (Standard)
Category:
Cat. No.: HY-162882
CAS No.: 2482713-67-5
Research Areas:
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .
Cat. No.: HY-161523
CAS No.: 2810137-86-9
Target:
Research Areas:
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .
Cat. No.: HY-180186
CAS No.: 3069916-11-3
Target:
Research Areas:
Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 1.7 nM. Xanthine oxidase-IN-20 exhibits outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Xanthine oxidase-IN-20 shows favorable safety profile. Xanthine oxidase-IN-20 can be used for hyperuricemia and gout research .
Cat. No.: HY-175309
CAS No.: 2516232-89-4
Target:
Research Areas:
URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC50 of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout .
Cat. No.: HY-189143
Target:
Research Areas:
Xanthine oxidase-IN-24 is an orally active mixed-type inhibitor of xanthine oxidase, with an IC50 of 0.051 μM and a Ki of 0.162 μM. Xanthine oxidase-IN-24 interacts with both free xanthine oxidase and the xanthine-xanthine oxidase complex, and reduces uric acid production in vivo. In a rat model of hyperuricemia induced by Potassium oxonate (HY-17511), Xanthine oxidase-IN-24 dose-dependently lowers serum uric acid levels, improves renal function-related biochemical parameters such as creatinine and urea nitrogen, and alleviates histopathological damage to liver and kidney tissues. Xanthine oxidase-IN-24 can be used in the research of hyperuricemia .
Cat. No.: HY-189695
CAS No.: 3133114-23-2
Target:
Research Areas:
URAT1-IN-18 is an orally effective URAT1 inhibitor. URAT1-IN-18 inhibits URAT1-mediated urate transport and renal urate reabsorption. URAT1-IN-18 exhibits low cytotoxicity in vitro, with less apoptosis and loss of mitochondrial membrane potential. URAT1-IN-18 shows moderate metabolic stability in rat liver microsomes. URAT1-IN-18 reduces serum uric acid levels in a hyperuricemia mouse model, protects renal tubular structure, and has good biosafety. URAT1-IN-18 can be used for research related to hyperuricemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
